Patents by Inventor Bryan L. Roth

Bryan L. Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF CIRCADIAN RHYTHMS AND USES THEREOF
    Publication number: 20230052740
    Abstract: Disclosed herein are, inter alia, compounds modulating MT1 and MT2 receptors' activity and methods of use thereof for treating MT1 and MT2 receptor-related conditions.
    Type: Application
    Filed: August 27, 2020
    Publication date: February 16, 2023
    Inventors: Brian K. Shoichet, Reed M. Stein, Margarita L. Dubocovich, Grant C. Glatfelter, Bryan L. Roth, Hye Jin Kang
  • Mu opioid receptor modulators
    Patent number: 11484525
    Abstract: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: November 1, 2022
    Assignees: The Regents of the University of California, Friedrich-Alexander-Universität Erlangen-Nürnberg, The Board of Trustees of the Leland Stanford Junior University, The University of North Carolina at Chapel Hill
    Inventors: Brian K. Shoichet, Henry Lin, Peter Gmeiner, Aashish Manglik, Brian Kobilka, Bryan L. Roth, Daniela Gisela Dengler
  • Compositions and Methods for the Treatment of Prader-Willi Syndrome
    Publication number: 20220117967
    Abstract: The invention provides pharmaceutical compositions and methods of use thereof for treating Prader-Willi syndrome. More specifically, the invention provides pharmaceutical compositions that when administered inhibit the G9a driven methylation of histone H3 lysine 9.
    Type: Application
    Filed: November 23, 2021
    Publication date: April 21, 2022
    Inventors: Yong-hui Jiang, Yuna Kim, Hyeong-min Lee, Jian Jin, Bryan L. Roth
  • Compositions and methods for the treatment of Prader-Willi syndrome
    Patent number: 11278550
    Abstract: The invention provides pharmaceutical compositions and methods of use thereof for treating Prader-Willi syndrome. More specifically, the invention provides pharmaceutical compositions that when administered inhibit the G9a driven methylation of histone H3 lysine 9.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 22, 2022
    Assignees: Duke University, The University of North Carolina at Chapel Hill
    Inventors: Yong-hui Jiang, Yuna Kim, Hyeong-min Lee, Jian Jin, Bryan L. Roth
  • MU OPIOID RECEPTOR MODULATORS
    Publication number: 20210052548
    Abstract: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
    Type: Application
    Filed: July 6, 2020
    Publication date: February 25, 2021
    Applicants: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Brian K. Shoichet, Henry Lin, Peter Gmeiner, Aashish Manglik, Brian Kobilka, Bryan L. Roth, Daniela Gisela Dengler
  • MU opioid receptor modulators
    Patent number: 10702498
    Abstract: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: July 7, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN-NÜRNBERG, THE BOARD OF TRUSTEES OFTHE LELAND STANFORD JUNIOR UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Brian K. Shoichet, Henry Lin, Peter Gmeiner, Aashish Manglik, Brian Kobilka, Bryan L. Roth, Daniela Gisela Dengler
  • MU OPIOID RECEPTOR MODULATORS
    Publication number: 20200109126
    Abstract: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
    Type: Application
    Filed: January 5, 2018
    Publication date: April 9, 2020
    Inventors: Brian K. Shoichet, Peter Gmeiner, Harald Hübner, Bryan L. Roth, Daniela Gisela Dengler, Aashish Manglik, Brian Kobilka
  • Compositions and Methods for the Treatment of Prader-Willi Syndrome
    Publication number: 20190201402
    Abstract: The invention provides pharmaceutical compositions and methods of use thereof for treating Prader-Willi syndrome. More specifically, the invention provides pharmaceutical compositions that when administered inhibit the G9a driven methylation of histone H3 lysine 9.
    Type: Application
    Filed: May 17, 2017
    Publication date: July 4, 2019
    Inventors: Yong-hui Jiang, Yuna Kim, Hyeong-min Lee, Jian Jin, Bryan L. Roth
  • MU OPIOID RECEPTOR MODULATORS
    Publication number: 20190076398
    Abstract: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
    Type: Application
    Filed: June 30, 2016
    Publication date: March 14, 2019
    Inventors: Brian K. Shoichet, Henry Lin, Peter Gmeiner, Aashish Manglik, Brian Kobilka, Bryan L. Roth, Daniela Gisela Dengler
  • SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS
    Publication number: 20140243333
    Abstract: A functionalized polycyclic compound can have a structure of Formula 1 or salt, prodrug, analog, or derivative thereof, which compound can be prepared by providing a diene; reacting the diene with a dienophile under sufficient conditions for a combined Diels-Alder/acylation reaction so as to provide a polycyclic compound having a carboxylic acid; and coupling the carboxylic acid with an amine-containing compound or a hydroxyl-containing compound so as to form an amide or an ester and producing a compound having a structure of Formula 1. The compound can be used for modulating an opioid receptor, which can be conducted by administering to an opioid receptor a functionalized polycyclic compound as described herein in an effective amount to modulate the functionality of the opioid receptor. Such opioid modulation can provide a biological benefit to a subject.
    Type: Application
    Filed: May 13, 2014
    Publication date: August 28, 2014
    Applicants: University of Kansas, University of North Carolina
    Inventors: Jeffrey Aube, Bryan L. Roth, Partha Ghosh, Kevin J. Frankowski
  • Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
    Patent number: 8735391
    Abstract: A functionalized polycyclic compound can have a structure of Formula 1 or salt, prodrug, analog, or derivative thereof, which compound can be prepared by providing a diene; reacting the diene with a dienophile under sufficient conditions for a combined Diels-Alder/acylation reaction so as to provide a polycyclic compound having a carboxylic acid; and coupling the carboxylic acid with an amine-containing compound or a hydroxyl-containing compound so as to form an amide or an ester and producing a compound having a structure of Formula 1. The compound can be used for modulating an opioid receptor, which can be conducted by administering to an opioid receptor a functionalized polycyclic compound as described herein in an effective amount to modulate the functionality of the opioid receptor. Such opioid modulation can provide a biological benefit to a subject.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: May 27, 2014
    Assignee: University of Kansas
    Inventors: Jeffrey Aube, Bryan L. Roth, Partha Ghosh, Kevin J. Frankowski
  • SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS
    Publication number: 20100256142
    Abstract: A functionalized polycyclic compound can have a structure of Formula 1 or salt, prodrug, analog, or derivative thereof, which compound can be prepared by providing a diene; reacting the diene with a dienophile under sufficient conditions for a combined Diels-Alder/acylation reaction so as to provide a polycyclic compound having a carboxylic acid; and coupling the carboxylic acid with an amine-containing compound or a hydroxyl-containing compound so as to form an amide or an ester and producing a compound having a structure of Formula 1. The compound can be used for modulating an opioid receptor, which can be conducted by administering to an opioid receptor a functionalized polycyclic compound as described herein in an effective amount to modulate the functionality of the opioid receptor. Such opioid modulation can provide a biological benefit to a subject.
    Type: Application
    Filed: September 25, 2009
    Publication date: October 7, 2010
    Inventors: Jeffrey Aube, Bryan L. Roth, Partha Ghosh, Kevin J. Frankowski